论文部分内容阅读
目的:探讨尤瑞克林治疗缺血性脑卒中的临床效果。方法:对2011年2月至2012年7月我院神经内科收治的84例缺血性脑卒中患者进行随机分组,对照组42例,给予控制血压、降糖、抗血小板聚集、调脂及改善脑循环等基础治疗。治疗组42例,在基础治疗的同时加尤瑞克林治疗。对两组患者治疗前后的NIHSS评分、mRS评分、ADL评分以及不良反应情况进行比较。结果:两组患者治疗前后NIHSS评分、mRS评分、ADL评分均有不同程度的改善,治疗组的改善情况更为明显,差异具有统计学意义(P<0.05)。同常规组比较,治疗组不良反应未见明显增加。结论:采用尤瑞克林治疗缺血性脑卒中的临床疗效比较显著,安全性也值得肯定,可进行临床推广。
Objective: To investigate the clinical efficacy of erilecin in the treatment of ischemic stroke. Methods: Eighty-four patients with ischemic stroke admitted to Department of Neurology in our hospital from February 2011 to July 2012 were randomly divided into control group (42 cases), control of blood pressure, hypoglycemic, anti-platelet aggregation, lipid-lowering and improvement Cerebral circulation and other basic treatment. In the treatment group, 42 cases were treated with urelin during the basic treatment. NIHSS scores, mRS scores, ADL scores and adverse reactions before and after treatment were compared between two groups of patients. Results: The NIHSS score, mRS score and ADL score of both groups improved to some extent before and after treatment, and the improvement of the treatment group was more obvious. The difference was statistically significant (P <0.05). Compared with the conventional group, the treatment group showed no significant increase in adverse reactions. Conclusion: The clinical curative effect of using ureclin in the treatment of ischemic stroke is significant, the safety is also worthy of affirmation, and the clinical promotion can be carried out.